Intermediate AMD Epidemiology Forecast 2026-2035

Intermediate age-related macular degeneration (AMD) is a progressive retinal disorder that contributes substantially to global visual impairment. According to Hirak Debnath et al., 2025, AMD accounts for about 8.7% of global blindness and could affect nearly 288 million people by 2040. As per Ramya Gnanaraj et al., 2025, global prevalence reached 196 million in 2020. According to the intermediate AMD epidemiology forecast, the growing aging population is expected to significantly expand the patient pool worldwide.

Intermediate AMD Epidemiology Forecast Report Coverage

The analyst's “Intermediate AMD Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of intermediate AMD. It projects future incidence and prevalence rates of intermediate AMD across populations. The study covers age, gender, and type as major determinants of the intermediate AMD population. The report highlights patterns in the prevalence of intermediate AMD over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of intermediate AMD in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Intermediate AMD Understanding: Disease Overview

Intermediate age-related macular degeneration (AMD) is a progressive eye disorder that affects the macula, the central portion of the retina responsible for sharp vision. It occurs due to the accumulation of drusen, which are yellow deposits of lipids and proteins beneath the retina, along with retinal pigment epithelium dysfunction. These changes gradually impair photoreceptor function and central vision. Intermediate AMD represents the stage between early and advanced AMD and is characterized by the presence of larger drusen and pigmentary abnormalities. The condition can progress to two advanced forms: geographic atrophy, a type of dry AMD, or neovascular AMD, also known as wet AMD.

Intermediate AMD Epidemiology Perspective

The intermediate AMD epidemiology division provides information on the patient pool from historical to current periods, as well as projected trends for each of the 8 major markets. The analyst provides both current and predicted trends for the intermediate AMD epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for intermediate AMD and its trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Lisa Lüdtke et al., 2024, analysis of 1,418 fundus images reported intermediate age-related macular degeneration in 3.88% of individuals, while early AMD was detected in 6.49% and late AMD in 0.07%, indicating a moderate prevalence of intermediate disease stages in screened populations.
• As per Lisa Lüdtke et al., 2024, intermediate AMD was most frequently observed in individuals aged 60-79 years, whereas early disease changes appeared mainly in 40-69 years, and late AMD occurred primarily in people over 80 years, highlighting strong age-related progression patterns.
• According to Rohan Bir Singh et al., 2025, intermediate AMD prevalence among Medicare-enrolled individuals was significantly higher in adults aged 85 years and older (15.84-16.75%) compared with 5.08-5.38% in younger elderly groups, demonstrating a sharp increase with advancing age.
• As per Rohan Bir Singh et al., 2025, intermediate AMD showed higher prevalence in females (7.7-8.3%) than males (5.6-6.0%), with racial variation also observed, including higher prevalence in White populations (7.5-8.0%) compared with other ethnic groups.
• According to Bo Jiang et al., 2023, global age-related macular degeneration prevalence rose from 3.58 million cases in 1990 to 7.79 million in 2019, with higher disease burden in adults over 50 years and females, reflecting increasing incidence and disability burden worldwide.

Country-wise Intermediate AMD Epidemiology

The intermediate AMD epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Intermediate Age-Related Macular Degeneration (AMD) shows notable variation across major global regions, reflecting demographic and methodological differences in studies. According to Rohan Bir Singh et al., 2025, the global prevalence of AMD among adults aged 45 years and older was estimated at 8.7%, with projections reaching nearly 288 million cases by 2040. In the United States, crude prevalence rates among individuals aged 40 years and above were reported at 11.64% for early-stage AMD and 0.94% for late-stage disease, affecting approximately 18.34 million and 1.49 million people, respectively. According to Hirak Debnath et al., 2025, in India AMD affects about 1.4-3.1% of the population, highlighting the growing epidemiological and healthcare burden across these regions.

Intermediate AMD: Treatment Overview

Intermediate age-related macular degeneration treatment primarily focuses on slowing disease progression and reducing the risk of advancing to severe stages. Nutritional supplementation based on the Age-Related Eye Disease Study (AREDS) formulation, containing antioxidants, zinc, copper, lutein, and zeaxanthin, is widely recommended. Lifestyle modifications such as smoking cessation, a nutrient-rich diet, and regular eye examinations also play an important role in disease management. Although no curative therapy exists for intermediate AMD, ongoing monitoring with retinal imaging helps detect progression early. Patients at higher risk may receive preventive interventions and guidance to delay the onset of advanced AMD forms.

Key Questions Answered

• What are the key findings of intermediate AMD epidemiology in the 8 major markets?
• What will be the total number of patients with intermediate AMD across the 8 major markets during the forecast period?
• What was the country-wise intermediate AMD epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of intermediate AMD patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of intermediate AMD during the forecast period of 2026-2035?
• What are the currently available treatments for intermediate AMD?
• What are the disease risks, signs, symptoms, and unmet needs of intermediate AMD?

Scope of the Intermediate AMD Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of intermediate AMD based on several factors.
• Intermediate AMD Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The intermediate AMD report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.